IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
This study has been completed.
Sponsor:
Luitpold Pharmaceuticals
Information provided by (Responsible Party):
Luitpold Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00236938
First received: October 10, 2005
Last updated: May 11, 2015
Last verified: May 2015
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.
| Condition | Intervention | Phase |
|---|---|---|
| Anemia | Drug: Venofer and stable erythropoietin (EPO) regimen Drug: stable erythropoietin (EPO) regimen | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis |
Resource links provided by NLM:
Further study details as provided by Luitpold Pharmaceuticals:
Primary Outcome Measures:
- Mean Change From Baseline to the Highest Hemoglobin up to Day 71 [ Time Frame: Change from Baseline up to Day 71 ]
Secondary Outcome Measures:
- The Mean Change From Baseline to the Highest Serum Transferrin Saturation (TSAT) up to Day 71 [ Time Frame: Change from Baseline up to Day 71 ]
- The Mean Change From Baseline to the Highest Ferritin up to Day 71 [ Time Frame: Change from Baseline up to Day 71 ]
- The Mean Change From Baseline to the Highest Reticulocyte Count up to Day 71 [ Time Frame: Change from Baseline up to Day 71 ]
| Enrollment: | 121 |
| Study Start Date: | July 2002 |
| Study Completion Date: | October 2004 |
| Primary Completion Date: | September 2004 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Group A
Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
|
Drug: Venofer and stable erythropoietin (EPO) regimen
Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
Other Name: Iron Sucrose
|
|
Active Comparator: Group B
Stable erythropoietin (EPO) dose and no supplemental iron.
|
Drug: stable erythropoietin (EPO) regimen
Stable erythropoietin (EPO) dose and no supplemental iron.
Other Name: EPO
|
Detailed Description:
This is an open-label, prospective study comparing IV iron supplementation to standard care in anemic patients undergoing peritoneal dialysis. After successfully completing a 6 month enrollment period, qualifying patients were randomized to receive 1000mg of IV iron over a four week period, or no iron supplementation. Erythropoietin regimen was to remain stable. Patients were followed to day 71 for safety and efficacy.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Hemoglobin >= 9.5 and <= 11.5 g/dL.
- Ferritin <= 500 ng/ml.
- Serum Transferrin Saturation (TSAT) <= 25%.
- Stable erythropoietin (EPO) Regimen for 8 weeks.
- No iron for last 4 weeks before randomization.
Exclusion Criteria:
- Known Sensitivity to Iron Sucrose.
- Suffering concomitant severe diseases of the liver & cardiovascular system.
- Pregnancy / Lactation.
- Inadequate dialysis.
- Current treatment for asthma.
- Significant blood loss.
- Probability of need for transfusion or transfusion within 1 week of enrollment.
- Anticipated major surgery.
- Hemochromatosis / hemosiderosis.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236938
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236938
Sponsors and Collaborators
Luitpold Pharmaceuticals
Investigators
| Study Director: | Antoinette Mangione, MD, PharmD | Luitpold Pharmaceuticals |
More Information
Publications:
| Responsible Party: | Luitpold Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00236938 History of Changes |
| Other Study ID Numbers: |
1VEN02021 / 1VEN02022 |
| Study First Received: | October 10, 2005 |
| Results First Received: | January 14, 2009 |
| Last Updated: | May 11, 2015 |
Keywords provided by Luitpold Pharmaceuticals:
|
iron peritoneal dialysis anemia |
Additional relevant MeSH terms:
|
Iron Ferric oxide, saccharated Ferric Compounds Epoetin Alfa Trace Elements |
Micronutrients Growth Substances Physiological Effects of Drugs Hematinics |
ClinicalTrials.gov processed this record on June 23, 2017